Hengbang Wang

5PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 09, 2026
Effects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia.

|Sep 04, 2024
Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.

Hengbang Wang, Yun Yang, Zi Chen

|Nov 16, 2023
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.

Nehal J Lakhani, Drew Rasco, Hengbang Wang

|Apr 19, 2023
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

Sikander Ailawadhi, Zi Chen, Bo Huang

|Sep 01, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.

Jing Deng, Aneel Paulus, Douglas D Fang

Pageof 1

Frequent Collaborators

5 joint publications

Yifan Zhai

5 joint publications

Dajun Yang

4 joint publications

Lichuang Men

3 joint publications

Tommy Fu